The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients
Effect of Drug, Migraine Disorders
About this trial
This is an interventional treatment trial for Effect of Drug focused on measuring migraine, lacosamide, Egypt
Eligibility Criteria
Inclusion Criteria: Naive migraine patients according to the International Classification of Headache Disorders 3rd edition aged 10-55 years, Exclusion Criteria: Patients with major neurological disorders such as ( epilepsy, ischemic or hemorrhagic stroke, multiple sclerosis, mitochondrial diseases, brain tumors, and patients with essential tremors. patients with major systemic diseases such as malignancy, collagen diseases, liver diseases, and renal diseases. patients with cardiovascular diseases like hypertension (systolic blood pressure of more than 130 and/or diastolic blood pressure of more than 85 mm/Hg on at least three different occasions, diabetes (fasting plasma glucose level >126 mg/dl and/or a casual plasma glucose >200 mg/dl and/or HbA1C more than 6.5. patients with valvular and ischemic heart diseases, patients who received prophylactic treatment for migraine, patients with any contraindications to lacosamide.
Sites / Locations
- Kafr Elsheikh University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
lacosamide group
control group
We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.